If you have been reading about triple agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
The welfare of farmed insects concerns treatment of insects raised for animal feed, as food or pet food, and other purposes such as honey and silk, for use in generating recombinant proteins, or for biological control applications.
=== With insulin === Carbohydrate counting may be used with either a fixed insulin dosage or with a more flexible insulin dosage. Carb counting for fixed insulin dosage is done in the same manner as carbohydrate counting without insulin. The only difference is that insulin is administered with the meal. With more flexible insulin dosage, the insulin is administered in regards to the amount of carbohydrate consumed. The insulin amount will vary based on the amount of carbohydrates consumed.
In 1993, True came in contact with the Tarahumara or Rarámuri runners from Chihuahua, Mexico. In 1994, he began spending his winters running in the Copper Canyons, where he built a hut and began establishing a relationship with the Tarahumara natives.
== Further reading == Laurence J. Alison, Marie Eyre: Killer in the Shadows: The Monstrous Crimes of Robert Napper. Pennant Books 2009, ISBN 978-1-906015-49-7. Kevin Brewer: Psychology and Crime. Heinemann Educational Publishers 2000, ISBN 978-0-435-80653-8. Paul Britton: The Jigsaw Man. Corgi Books 1998, ISBN 978-0-552-14493-3. Colin Evans: A Question of Evidence: The Casebook of Great Forensic Controversies, from Napoleon to O.J. Wiley 2002, ISBN 978-0-471-44014-7. Mike Fielder: The Murder of Rachel Nickell. John Blake 2000, ISBN 978-1-85782-338-7. Alex Handscombe: Letting Go: A true story of murder, loss and survival by Rachel Nickell's son. Harper Element 2017, ISBN 978-0008144296. André Hanscombe: The Last Thursday in July. Century 1996 / Arrow 1997, ISBN 978-0-09-917512-4. David Kessler: Rachel Nickell, House of Solomon Ltd, 2001, ISBN 978-1-904037-03-3. Keith Pedder: The Rachel Files, John Blake 2002, ISBN 978-1-904034-30-8. Keith Pedder: Murder on the Common: The Secret Story of the Murder That Shocked a Nation. John Blake 2003, ISBN 978-1-84454-057-0. Colin Stagg, David Kessler: Who Really Killed Rachel? Greenzone Publishing 1999, ISBN 978-0-9582027-2-5. Colin Stagg, David Kessler: The Lizzie James Conspiracy. House of Solomon 2001, ISBN 978-1-904037-00-2. Colin Stagg, Ted Hynds: Pariah: Colin Stagg. Pennant Publishing 2007, ISBN 978-1-906015-10-7. Brent E. Turvey: Criminal Profiling: An Introduction to Behavioral Evidence Analysis Academic Press 2002, ISBN 978-0-12-705041-6.
Sources: en.wikipedia.org
=== Certolizumab pegol === Certolizumab pegol is a recombinant antigen-binding fragment antibody that is attached to a 40kDa polyethylene glycol. The addition of polyethylene glycol, or PEGylation, increases bioavailability, drug stability, and plasma half-life. It was found to have efficacy over placebo medications for 10 weeks in the treatment of moderate to severe Crohn's disease in one large trial. It is not used in the treatment of ulcerative colitis, but it is used in the treatment of rheumatoid arthritis, active psoriatic arthropathy, and ankylosing spondylitis.
Scott Tanner is a Canadian scientist, inventor, and entrepreneur. His areas of expertise include mass spectroscopy, especially inductively coupled plasma mass spectrometry (ICP-MS), and mass cytometry. Tanner is best known for his work on the fundamentals of inductively coupled plasma mass spectrometry, for the invention of mass cytometry, and co-founding (with Dmitry Bandura, Vladimir Baranov and Olga Ornatsky) DVS Sciences in 2004,(acquired by Fluidigm in 2014 and then renamed to Standard BioTools in 2022) the company that first commercialized the instrument and reagents of mass cytometry.
The design of multi-layer packaging system has been recognized as the state-of-the-art in food packaging application for its versatility, processability and efficacy. Each layer can be made of different materials and provides a key functionality for the whole structure, such as improved mechanical properties, chemical stability, barrier properties and anti-microbial properties. However, the use of such complex structures significantly reduces its recyclability (except for a few cases). Recently, the application of protective coating on commercially available packaging materials (such as PET, PP, PLA cardboard or biopolymer) represents a potential solution to deal with the increasing environmental impact due to both food and packaging waste. Barcodes have been used for decades in packaging many products. 2D barcodes used in autocoding are increasingly applied to food packaging to ensure that products are correctly packaged and date coded. The ability of a package to fully empty or dispense a viscous food is somewhat dependent on the surface energy of the inner walls of the container. The use of superhydrophobic surfaces is useful but can be further improved by using new lubricant-impregnated surfaces.
Many women marry before reaching 18, which is their legal marriageable age; child marriages are not uncommon, especially in rural areas. In large parts of Hindu northern India, moreover, a form of territorial exogamy is observed in which a bride marries out of her natal village, and her parents do not visit her in her married home; the annual rite raksha bandhan, during which married women return to their natal homes, has served both to affirm bonds with their natal families and offer a recourse in times of marital stress. Modern Indian Muslim society is highly diverse, divided by local languages, distinct cultural backgrounds, and internal social classes. However, Indian Muslims have much lower college enrollment, less access to banking services, and far fewer formal jobs than average. Additionally, due to safety worries and unfair housing practices, many urban Muslims have been forced to move into separated neighbourhoods that often lack basic public services. Still, Muslim families regularly see higher rates of child survival compared to other religious and social groups. The Saint Thomas Christians, also known as Syrian Christians, trace their history to the arrival ashore in South India of St Thomas the Apostle in the 1st century CE, though inscriptions place their origins to the mid-first-millennium CE; they spread along the Malabar Coast of the state of Kerala, and have their distinctive liturgical traditions. Indian Catholics date their presence to 1500 soon after the arrival of Vasco da Gama in Calicut.
Later in September Roche announced its intention to acquire Tusk Therapeutics for up to €655 million ($759 million) expanding Roche's oncology pipeline. Tusk announced that the anti-CD38 antibody it is developing will be spun off to form a new company, Black Belt Therapeutics. In late November, the company announced that Genentech would acquire Jecure Therapeutics, gaining access to Jecure's portfolio of NLRP3 inhibitors developed to fight inflammatory diseases like non-alcoholic steatohepatitis and liver fibrosis. In February 2019, the business announced it would acquire gene therapy company, Spark Therapeutics, for US$4.3 billion ($114.50 per share) adding Spark's gene therapy portfolio to its previous acquired assets. Spark has an already approved treatment for Leber's congenital amaurosis, Luxturna – priced at US$850,000 per patient. The offer to acquire Spark Therapeutics was extended to May 2019 after Roche was unable to garner majority support from Spark shareholders. A second gene therapy-related action came in December with the US$1.15 billion acquisition of non-United States rights to an investigational duchenne muscular dystrophy gene therapy developed by Sarepta Therapeutics. In November, Roche acquired Promedior and its lead treatment – PRM-151 – for the treatment of idiopathic pulmonary fibrosis, for $390 million upfront and another $1 billion in milestone payments.
Sources: en.wikipedia.org
=== Continuous-flow fast atom bombardment === CE can be coupled to fast atom bombardment ionization using a continuous flow interface. The interface must match the flow rate between the two systems. The CF-FAB requires a relatively high flow rate but CE need low flow rate for better separation. A make-up flow can be used using a sheath flow or liquid junction.
=== Topical application === Topically applied sodium hyaluronate can facilitate the absorption of biomacromolecules, i.e. pharmaceuticals, and function like a nanocarrier. Its effects on skin depend on the hyaluronate formulation and skin health: In barrier-deficient skin it restricted the delivery of biomacromolecules to the stratum corneum and viable epidermis. In normal skin, low-molecular weight hyaluronate (5 kDa) enhanced penetration into the epidermis. Transepidermal water loss increased by 55.5% with low-molecular weight, and was reduced by 28% with crosslinked resilient, and by 16% with HMW. Its efficacy against wrinkles has not been tested in clinical trials. Dry, scaly skin, such as that caused by atopic dermatitis, may be treated with lotion or another skin product containing sodium hyaluronate as its active ingredient. After instillation into the lung, higher molecular weight hyaluronate appears to persist longer in the lung but if > 215 kD there was poor lung penetration and mucociliary clearance. Hyaluronate could allow access to lymph nodes draining the pulmonary bed.
=== Quantitative direct and indirect test === The quantitative direct and indirect test (QDIRT) was developed in 2008 by Christopher Gibbons and colleagues as a means for the evaluation of postganglionic sudomotor function outside of specialized autonomic testing centers. It combines elements of TST, QSART, and the silicone imprint method. Similar to QSART, it involves the iontophoresis of 10% acetylcholine solution to induce axon-reflex sweating; however, it utilizes an automated imaging analysis software that is less technically complex. Prior to iontophoresis, the skin is dried and covered with an indicator dye consisting of povidone-iodine mixed with corn starch and mineral oil. The indicator dye changes color with the onset of sweating. Digital photographs of the color change are recorded every 15 seconds over approximately 7 minutes. Spatial and temporal analysis of sweat droplets as well as direct and indirect sweat response are measured. Although QDIRT is less technically demanding than QSART or TST, it still requires trained staff and an environmentally controlled room; iontophoresis may cause skin irritation or burning; the skin areas studied using QDIRT are not pre-defined, thus limiting the interindividual comparability of the test; and little normative or performance data are available.
=== Aflatoxin susceptibility === Copra is highly susceptible to the growth of molds and their production of aflatoxins if not dried properly. Aflatoxins can be highly toxic, and are among the most potent known natural carcinogens, particularly affecting the liver. Aflatoxins in copra cake, fed to animals, can be passed on to milk or meat from livestock, leading to human illnesses.
There was a history and belief in England that the foreign manager could not be successful. Now you have a different feeling, now you think only foreign managers can be successful. That is wrong as well. I believe I contributed to the change in attitude about foreign managers. That can look pretentious but I don't think it is at all. I can show some articles where people tried to prove that the foreign managers can never win an English championship. That has changed and I have certainly contributed to that. But I am also one of the few who also defends English managers.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。